Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis.

Front Immunol · 2025 · PMC11911185 · PMID 40098958

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The average relative fluorescent signal following rAAV9-microdystrophin and combination treatment was reduced by 26% (19669 ± 3526) compared to rAAV9-microdystrophin treated mice (26468 ± 3644), but this did not reach statistical significance ( Supplementary Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.